Loading…
Onconetix, Inc. is projected to decline to $1.09 by 2027, a -7% move from its current price of $1.17. ONCO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.06 | $1.17 | $1.30 | 0.00% |
| May 30 | $1.01 | $1.17 | $1.35 | 0.00% |
| May 31 | $0.9806 | $1.17 | $1.40 | 0.00% |
| Jun 1 | $0.9541 | $1.17 | $1.43 | +0.01% |
| Jun 2 | $0.9314 | $1.17 | $1.47 | +0.01% |
| Jun 3 | $0.9114 | $1.17 | $1.50 | +0.01% |
| Jun 4 | $0.8933 | $1.17 | $1.53 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8933 | $1.17 | $1.53 | +0.01% |
| Week 2 | $0.7989 | $1.17 | $1.71 | +0.02% |
| Week 3 | $0.7333 | $1.17 | $1.87 | +0.03% |
| Week 4 | $0.6823 | $1.17 | $2.01 | +0.04% |
| Week 5 | $0.6402 | $1.17 | $2.14 | +0.05% |
| Week 6 | $0.6044 | $1.17 | $2.27 | +0.06% |
| Week 7 | $0.5733 | $1.17 | $2.39 | +0.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Onconetix, Inc. is a biotechnology company focused on research, development, and commercialization in the United States, the European Union, and Non-European Union. The company concentrates on solutions for men’s health and oncology and offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Onconetix has license arrangements with LabCorp to develop and commercialize Proclarix and other products, and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc.
in December 2023. It was founded in 2018 and is headquartered in Cincinnati, Ohio.
Onconetix, Inc. (ONCO) operates as a healthcare stock with a current price of $1.24 and a market capitalization of $1.42M, ranking at 5504. The stock trades in the healthcare sector and is positioned as a micro-cap biotechnology play with exposure to men’s health and oncology tests.
The price outlook presented in the forecasts spans from 2026 through 2050, showing a path that fluctuates across years but trends toward higher average levels in the long run. The model’s yearly outlook includes a range of possible prices (min, avg, max) and ROI for each year, highlighting notable volatility and mixed near-term momentum.
A major floor 6.0% below — a decisive break under it would weaken the trend.
The nearest floor, 6.0% below — buyers have tended to step in here.
The nearest ceiling, 556.4% above — a clean break opens room to run.
A major ceiling 7806.0% above — clearing it would confirm fresh momentum.
Key ONCO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ONCO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.20 | Sell | $1.42 | Sell |
| MA 10 | $2.17 | Sell | $2.12 | Sell |
| MA 20 | $3.72 | Sell | $3.86 | Sell |
| MA 50 | $10.77 | Sell | $13.47 | Sell |
| MA 100 | $34.37 | Sell | $50.68 | Sell |
| MA 200 | $88.13 | Sell | $1,170.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 23.25 | Buy |
| Stoch RSI (14) | 14.18 | Buy |
| CCI (20) | -107.52 | Sell |
| Williams %R (14) | -97.65 | Info |
| MACD (12,26,9) | 0.33 | Buy |
| ROC (12) | -69.21 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 2.35 | Buy |
| TRIX (15) | -4.89 | Sell |
| Awesome (5,34) | -4.28 | Sell |
| Ultimate (7,14,28) | 9.70 | Buy |
| Momentum (10) | -2.91 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 0.78 | Buy |
| ADX (14) | 44.63 | Sell |
| ATR (14) | 0.62 | Info |
The 30-day technical picture shows a neutral stance with RSI(14) at 20, indicating relatively subdued momentum. The stock’s moving averages sit well above current levels, with SMA50 at $11.78 and SMA200 at $89.50, suggesting a wide gap between price and trend lines.
Key near-term levels include a support at $1.10 and a resistance at $9.10. The 30-day price range spans from a low of $0.6095 to a high of $2.52, and the security exhibits high historical volatility, with an annualized volatility of 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.10 | $1.17 | $1.58 | 0% | Neutral | |
| $0.7865 | $1.09 | $1.64 | -7% | Neutral | |
| $0.5818 | $0.8579 | $1.37 | -27% | Bearish | |
| $0.565 | $0.877 | $1.47 | -25% | Bearish | |
| $0.6229 | $1.01 | $1.77 | -13% | Neutral | |
| $0.7836 | $1.33 | $2.40 | +14% | Neutral | |
| $0.8045 | $1.43 | $2.65 | +22% | Bullish | |
| $0.7051 | $1.30 | $2.49 | +11% | Neutral | |
| $0.6815 | $1.31 | $2.56 | +12% | Neutral | |
| $0.5958 | $1.19 | $2.38 | +2% | Neutral | |
| $0.8285 | $1.84 | $4.05 | +57% | Bullish | |
| $1.15 | $2.56 | $5.89 | +119% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.10 | $1.17 | $1.40 | +0.00% |
| June 2026 | $1.03 | $1.23 | $1.53 | +5.08% |
| July 2026 | $0.9606 | $1.17 | $1.49 | -4.70% |
| August 2026 | $0.9087 | $1.12 | $1.46 | -4.13% |
| September 2026 | $0.9385 | $1.17 | $1.55 | +4.42% |
| October 2026 | $0.9394 | $1.19 | $1.59 | +1.13% |
| November 2026 | $0.8878 | $1.13 | $1.53 | -4.64% |
| December 2026 | $0.8953 | $1.15 | $1.58 | +1.73% |
Click any year to see its month-by-month ONCO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ONCO is projected to trade between $1.10 and $1.58, averaging $1.17 — a potential gain of 0% from today's $1.17. Price action looks broadly range-bound.
Onconetix, Inc.'s 2027 outlook centres on $1.09, within a $0.7865 to $1.64 range. That is -7% versus the projected 2026 average. That marks a -7% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, ONCO could reach as high as $1.37, with a base case around $0.8579 and support toward $0.5818 — roughly -27% from $1.17. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect ONCO to range from $0.565 to $1.47 through 2029. The $0.877 average target implies a -25% move from current prices. That is up +2% on the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
The ONCO price prediction for 2030 points to an average of $1.01 (low $0.6229, high $1.77) — a potential decline of -13% on today's $1.17. Price action looks broadly range-bound.
In 2031, ONCO is projected to trade between $0.7836 and $2.40, averaging $1.33 — a potential gain of +14% from today's $1.17. That is up +31% on the projected 2030 average. A consolidation phase looks the most probable path here.
Onconetix, Inc.'s 2032 outlook centres on $1.43, within a $0.8045 to $2.65 range. That is up +7% on the projected 2031 average. That marks a +22% change versus current levels. Momentum favours further upside here.
By 2033, ONCO could reach as high as $2.49, with a base case around $1.30 and support toward $0.7051 — roughly +11% from $1.17. A consolidation phase looks the most probable path here.
Expect ONCO to range from $0.6815 to $2.56 through 2034. The $1.31 average target implies a +12% move from current prices. That is up +1% on the projected 2033 average. Price action looks broadly range-bound.
The ONCO price prediction for 2035 points to an average of $1.19 (low $0.5958, high $2.38) — a potential gain of +2% on today's $1.17. A consolidation phase looks the most probable path here.
In 2040, ONCO is projected to trade between $0.8285 and $4.05, averaging $1.84 — a potential gain of +57% from today's $1.17. That is up +55% on the projected 2035 average. Momentum favours further upside here.
Onconetix, Inc.'s 2050 outlook centres on $2.56, within a $1.15 to $5.89 range. That is up +39% on the projected 2040 average. That marks a +119% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in ONCO today (≈ 854.700855 ONCO) could be worth
$2,189.08
+$1,189.08 (+119%) by 2050 · US Dollar
Based on the average projected ONCO price of $2.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ONCOwould be worth at today's price.
$1,000 invested in ONCO on May 27, 2025 (≈ 3.267974 ONCO) would be worth
$3.82
-$996.18 (-99.6%) today · 0.00× · US Dollar
Based on a ONCO entry price of $306 vs. today's $1.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.1 | $1,063.64 | +6.4% |
| 1 month ago | $7.42 | $157.68 | -84.2% |
| 3 months ago | $33 | $35.45 | -96.5% |
| 6 months ago | $139 | $8.42 | -99.2% |
| 1 year ago | $306 | $3.82 | -99.6% |
| All time (4.3y) ago | $9,758,000 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ONCO forecast.
Our base-case forecast reaches $2.30 around 2050.
Implied market cap at $2.30: $2.64M
The year-by-year forecast shows a mixed near-term path followed by longer-term upside. In 2026 the avg price is $1.24 with a 0% ROI, and sentiment is NEUTRAL. The 2027 forecast has an avg of $1.16 with a -6.7% ROI, and 2028 shows a further decline to an avg of $0.8914 with a -28.1% ROI.
2029’s avg is $0.9447 and -23.8% ROI, while 2030’s avg is $1.08 with a -12.7% ROI.
From 2031 onward, the outlook improves, with 2031 at avg $1.40 and 12.8% ROI, and 2032 at avg $1.52 with 22.9% ROI, signaling a bullish tilt beginning in the early 2030s. The forecast continues to show positive ROIs later in the decade and into 2040 (avg $1.93, ROI 55.9%) and 2050 (avg $2.76, ROI 122.8%). Sentiment shifts to BEARISH in the late 2020s, becomes NEUTRAL again in 2031-2035, and turns BULLISH in 2032 and beyond.
Tap a question to reveal the answer.
Avg $1.08, min $0.6648, max $1.89, ROI -12.7%, sentiment NEUTRAL.
The forecast shows a wide range of outcomes. In 2030 the avg price is $1.08 with ROI -12.7% and NEUTRAL sentiment, while later years project upside such as 2032 avg $1.52 (ROI 22.9%) and 2050 avg $2.76 (ROI 122.8%), indicating potential but with notable risk across years.
Yes, the max forecasted price by 2050 is $6.36 with ROI 122.8%.
RSI(14) is 20, indicating neutral to oversold momentum; support is at $1.10 and resistance at $9.10. The 30-day price range is $0.6095 to $2.52, with high annualized volatility at 200%.
Current price is $1.24 and market cap is $1.42M.
Onconetix, Inc. Community Discussion
0Share your Onconetix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.